BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
HAE - Haemonetics Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$104.60
DETAILS
HIGH:
$119.00
LOW:
$85.00
MEDIAN:
$105.00
CONSENSUS:
$104.60
DOWNSIDE:
3.30%
Stock News
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE
Aurora Investment Counsel acquired a new stake in Haemonetics Corporation (NYSE: HAE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,501 shares of the medical instruments supplier's stock, valued at approximately $1,913,000. Aurora Investment Counsel owned about 0.06% of Haemonetics as
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors
On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Haemonetics Q1 Earnings Call Highlights
Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses, while maintaining a disciplined stance on assumptions for the remainder of the year.
Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago.
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS's NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS's potential as an end-to-end HAE platform.
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
BOSTON, Aug. 3, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced publication of a study providing new evidence supporting the safety and efficacy of Haemonetics' VASCADE MVP ® XL venous vascular closure system in large-bore sheath procedures. The retrospective cohort study represents the largest reported cohort using the VASCADE MVP XL system to date.
Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Martin Madaus Elected to Haemonetics Board of Directors
BOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that Martin Madaus has been elected to the Company's Board of Directors, effective July 24, 2026. Dr. Madaus brings more than 30 years of leadership experience in the diagnostics and life sciences tools industries, having helped drive corporate strategy, commercial growth and operational transformation as both a chief executive officer and a board member.
American Capital Management Inc. Sells 7,500 Shares of Haemonetics Corporation $HAE
American Capital Management Inc. cut its stake in Haemonetics Corporation (NYSE: HAE) by 10.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,915 shares of the medical instruments supplier's stock after selling 7,500 shares during the quarter. American Capital Management Inc.
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE).
Ariel Small/Mid Cap Value Q2 2026 Portfolio Activity
The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quarter, falling short of both the Russell 2500 Value Index's +18.50% return and the +20.26% gain posted by the Russell 2500 Index. Live entertainment, media, and technology company, Sphere Entertainment Co. was the top contributor during the quarter on solid earnings and improving operating fundamentals. Shares of Prestige Consumer Healthcare moved lower following disappointing earnings, driven primarily by ongoing supply constraints in its eye care segment and extended lead times in the Middle East.
Price Targets
Haemonetics price target raised to $119 from $96 at Baird
$119.00
(was $108.22)
Robert W. Baird
Haemonetics price target raised to $118 from $95 at Barrington
$118.00
(was $104.65)
Barrington
Haemonetics price target raised to $105 from $90 at Raymond James
$105.00
(was $85.73)
Raymond James
Haemonetics price target raised to $96 from $88 at Baird
$96.00
(was $85.02)
Robert W. Baird
Haemonetics price target raised to $95 from $89 at Barrington
$95.00
(was $85.02)
Barrington
Haemonetics (HAE) PT Raised to $96 at BTIG
$96.00
(was $84.94)
Marie Thibault
·
BTIG
Haemonetics (HAE) PT Raised to $85 at Mizuho
$85.00
(was $78.20)
Anthony Petrone
·
Mizuho Securities
Haemonetics price target lowered to $89 from $94 at Barrington
$89.00
(was $52.24)
Barrington
Haemonetics price target lowered to $67 from $72 at Baird
$67.00
(was $51.55)
David Rescott
·
Robert W. Baird
Haemonetics price target lowered to $70 from $80 at Mizuho
$70.00
(was $57.39)
Anthony Petrone
·
Mizuho Securities
Haemonetics price target lowered to $81 from $99 at Baird
$81.00
(was $61.40)
Robert W. Baird
Haemonetics price target raised to $94 from $93 at Barrington
$94.00
(was $65.02)
Barrington
Haemonetics price target lowered to $80 from $90 at Mizuho
$80.00
(was $65.02)
Mizuho Securities
Haemonetics price target raised to $93 from $90 at Barrington
$93.00
(was $82.03)
Barrington
Haemonetics price target raised to $90 from $75 at Mizuho
$90.00
(was $81.11)
Mizuho Securities
Haemonetics price target raised to $99 from $87 at Baird
$99.00
(was $80.33)
Robert W. Baird
Haemonetics (HAE) PT Raised to $90 at Raymond James
$90.00
(was $73.91)
Andrew Cooper
·
Raymond James
Haemonetics price target raised to $88 from $85 at BTIG
$88.00
(was $66.20)
BTIG
Haemonetics price target lowered to $68 from $84 at Needham
$68.00
(was $55.64)
Mike Matson
·
Needham
Raymond James Upgrades Haemonetics (HAE) to Strong Buy
$120.00
(was $74.83)
Andrew Cooper
·
Raymond James